<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30002">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774617</url>
  </required_header>
  <id_info>
    <org_study_id>HHL/UFRJ-04</org_study_id>
    <secondary_id>CAAE 06343212.8.0000.5257</secondary_id>
    <nct_id>NCT01774617</nct_id>
  </id_info>
  <brief_title>Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List</brief_title>
  <official_title>Comparative Analysis of Indocyanine Green Clearance Test, Model for End Stage Liver Disease(MELD)Score, MELD-Na Score, Transient Elastography and Hepatic Venous Pressure Gradient to Evaluate Prognosis of Patients on Liver Transplant Waiting List</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guilherme Rezende</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a cohort to evaluate the power of different diagnostic tests in predicting the
      prognosis of patients with severe liver disease.

      Patients with decompensated liver cirrhosis on the waiting list for liver transplantation
      will be evaluated with comparison of different diagnostic tests according to the MELD score
      (Model for End-Stage Liver Disease), MELD-Na (Model for End-Stage Liver Disease and sodium),
      indocyanine green clearance test, hepatic venous pressure gradient and transient
      elastography.  All patients will be submitted to all the tests and prospectively followed
      for 6 months, to establish mortality and complications related to liver disease in order to
      define the value of each method to predict outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mortality within 6 months after evaluation, classifying as related or non-related to liver disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic liver failure and portal hypertension complications</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complications:
gastroesophageal variceal bleeding
worsening of hepatic encephalopathy
decompensated ascites and spontaneous bacterial peritonitis
hepatorenal syndrome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>whole sample</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Comparison of different diagnostic tests</intervention_name>
    <arm_group_label>whole sample</arm_group_label>
    <other_name>Hepatic venous pressure gradient measurement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the study will include patients (100 patients)

          -  were male and female

          -  aged between 18 and 69 years with chronic liver disease

          -  with MELD inclusion greater than or equal to 14 to 30

        Exclusion Criteria:

          -  they have been transplanted

          -  Have a diagnosis of primary malignant liver (HCC) signed by imaging tests performed

          -  MELD scores greater than 30.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guilherme FM Rezende, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guilherme Rezende, PhD</last_name>
    <phone>552199976292</phone>
    <email>g.rezende@superig.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Cerqueira, MD</last_name>
    <phone>552188890155</phone>
    <email>cerqueira@hucff.ufrj.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universit√°rio Clementino Fraga Filho / Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Cerqueira, MD</last_name>
      <phone>55-21-88890155</phone>
      <email>cerqueira@hucff.ufrj.br</email>
    </contact>
    <contact_backup>
      <last_name>Guilherme FM Rezende, MD PhD</last_name>
      <phone>55-21-99976292</phone>
      <email>g.rezende@superig.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandre Cerqueira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 22, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Guilherme Rezende</investigator_full_name>
    <investigator_title>Associate Professor, MD PhD</investigator_title>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>elastography</keyword>
  <keyword>Hepatic venous pressure gradient measurement</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
